today announced that data from the Company’s Phase 2a human challenge study of EDP-323 in healthy adults infected with ...

A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...

A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The U.S. Centers for Disease Control and Prevention's vaccine experts are expected to vote on expanding access to respiratory ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The U.S. Centers for Disease Control and Prevention’s vaccine panel voted to expand its recommendation for the use of ...

In a recent final analysis of a phase 3 trial, the bivalent respiratory syncytial virus prefusion F (RSVpreF ... as part of the process. Human editors reviewed this content before publication.

Pfizer (PFE) announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...